Study of data from metastatic ovarian cancer using multiple tests
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at metastatic ovarian cancer by analyzing many types of patient data (from “multi-omics,” which means different kinds of lab and biological information). It may help doctors better understand the disease and improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- You have been diagnosed with ovarian cancer confirmed by scans (imaging) and biopsy/pathology
- You have had ovarian cancer surgery, and any follow-up treatment related to your care
- You have not started any anti-cancer medicines before that surgery at the study hospital
- You can and are willing to sign consent for your medical data to be collected and used
- You can follow study instructions and complete required steps
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses lab testing to create a “map” of ovarian cancer cells one cell at a time, to better understand the disease. It likely helps researchers learn which cell types are involved, using samples collected around your surgery.
This study aims to use your tumor and blood samples to find the best treatment for your ovarian cancer. It may help tailor your care based on your unique cancer biology.
This study looks for cancer DNA in your blood to understand advanced ovarian cancer better. It helps doctors see how the disease changes over time and may improve future treatments.
This trial is creating a detailed registry of genetic changes found in ovarian tumors in Taiwan. It aims to better understand the disease by collecting tumor tissue and blood samples from patients with high-grade serous or clear cell ovarian, fallopian tube, or peritoneal cancer.
This study looks at certain substances in the body (called metabolic biomarkers) and how they relate to how well patients do after treatment. It is for women who have just been diagnosed with high-grade serous ovarian cancer and have not yet had any treatment.
This study looks at tumor tissue from ovarian cancer patients to find “biomarkers,” or lab signals, that may predict how the disease behaves or how it might respond to treatment. You may be asked for a biopsy of the relapsed (coming back) tumor or to use an existing archived tumor sample.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.